reporting season

One of the features of the FY20 reporting season was the excellent cashflow performance of most Australian small cap companies. With the onset of COVID-19, many...

I have a working theory that the September quarter earnings (Q3) coming out over the next few weeks are going to give excellent insight to the new normal. Q1 earnings...

Reporting season was a very busy time. Overall, it felt like the fairly low expectations going into the August results were broadly met. One area that was very...

As the dust settles on the highly anticipated August 2020 reporting season, it’s time to take stock of the major themes emerging from Australian listed companies and...

As the now-concluded earnings reporting season shows, the pandemic has created a distinct market of winners and losers - interspersed with a few plodders just getting...

On 13 May, we published a quick update on the progress of the ‘Most tipped big caps’, the 10 stocks that got the most votes in our reader survey at the start of the...

This reporting season was always going to be one to remember as corporates reported on the peak period of dislocation caused by COVID-19 and earnings estimates within...

The year has not been kind to Woodside and its peers in the oil and gas patch. In February, the company weathered Tropical Cyclone Damien – the most severe storm ever...

In December of 2019, when Livewire ran our annual Predictions and Top Picks survey, the bushfires consumed headlines and our worries as investors. In January, we...

Headlines during reporting season have claimed that ‘dividends have slowed to a trickle.’ In reality though, it is cash returns that have slowed to a trickle. Cash...

After a stellar year in 2019, where the share price gained 139%, online betting firm Pointsbet (ASX:PBH) was firmly in the sights of Livewire readers. The stock was...

Laser guidance manufacturer Electro Optic Systems (EOS) had an incredible run in 2019, with the share price appreciating four-fold. But contract and delivery delays on...

It hasn’t been a good year for Avita Therapeutics (ASX:AVH). The med-tech stock is the worst performer among Livewire readers’ 10 most-tipped small caps, down nearly...

I was asked yesterday whether I’m happy with the way the Forager Australian Shares Fund has recovered through August. I’m not happy, and won’t be for some time yet. I...

Melbourne-based biotech Mesoblast will achieve a world-first that could open up its drug pipeline to a massive market if it wins US Food and Drug Administration...

The August 2020 reporting season was always going to be very unusual, dominated not by company-specific factors, but instead by rising political tensions,...

There’s no doubt this year has been a shocker thanks to the pandemic. And the latest reporting season has got in on the act by providing us with another jolt to the...

Welcome to the FNArena Reporting Season Monitor for the August result season 2020. The Monitor reports ratings and consensus price target changes, along with brief...

Over the last few years, Paradigm Biopharmaceuticals (PAR) has grown from an unknown small cap to a $600 million dollar drug developer. With trials and approvals...

Artificial intelligence giant Appen notched up a miss on Thursday. But are the company’s lacklustre EBITDA results just a consequence of an unpredictable market and a...